
TSE:HHL
This summary was created by AI, based on 5 opinions in the last 12 months.
The Healthcare Leaders Income ETF (HHL-T) faces a challenging environment due to pressure on the US healthcare sector, notably from health insurance companies and policies affecting pharma costs. It maintains a diversified portfolio with roughly 20-23 large global healthcare names, focusing on pharmaceuticals (35%), healthcare equipment (25%), and biotech (14%). Experts recommend HHL for its balance of income generation and potential growth, especially when paired with ETFs like XHC for additional growth. Although the sector has been volatile and affected by political factors, some analysts believe the negativity surrounding it might be overdone, and recent inflows into the ETF suggest a rebound could be on the horizon. The demographic trends could further support a recovery as clarity emerges in the US healthcare landscape.
This invests in healthcare related securities, and believes the enhancement comes from an option strategy overlay. Like any other sector, this is fine when it is going up. This ETF tends to have a lot of volatility compared to some of the others. He doesn’t use this, so doesn’t know that much about it. It’s a fine product and he has no issues with it. It has a pretty significant yield, which tends to be what attracts a lot of people. Dividend yield of 8%+ right now.
A theme that he is very interested in. He doesn’t know what this REIT actually owns, but would assume you will have your pharmaceuticals, and hopefully the bio-technology space. Even if it doesn’t have bio-technology, you might want to look at having this in your portfolio, even at these levels. Yield is 7%, so he presumes they are writing covered calls against these positions.
The US healthcare bill having failed Friday puts some risk into the sector. He would be fine if it fell back to support levels, but would not step in today, otherwise it is a fine quality holding.